Richmond Pharmacology presents �Improving Clinical Trial Design�at the BAPU 4th 2-yearly Symposium 2012

The Belgian Association of Phase 1 Units (BAPU) will host its 4th 2-yearly symposium this year in Antwerp, taking place 9th November 2012. The focus of this year�s meeting is modernising and innovation in early clinical drug development towards 2020.Founded in January 2005, BAPU represents the Belgian phase I clinical research units from both the pharmaceutical industry and academia. One of its primary objectives is to facilitate collaboration between Belgian phase I units as well as international phase I units and regulatory authorities.Invited on behalf of BAPU, Dr Ulrike Lorch�s presentation on Improving Clinical Trial Design will describe the benefit of adaptive design in First into Human and Early Phase Combination Studies, showing how its use, compared to conventional study designs, can lead to comprehensive time savings in early research programs.Click here to view full program and to registerWatch our latest presentation on Adaptive Study Design

Latest news

Participant-Centred Recruitment and Retention: Driving Faster Answers in Clinical Trials.

December 18, 2025
Richmond Pharmacology is proud to announce the publication of an editorial by Elizabeth Romano, Director of Communications and Participant Engagement, in the Winter 2025 issue of the Journal for Clinical Studies.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event